Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methotrexate Injection USP, the company announced in a news release.
This approval provides oncology nurses and the broader healthcare community with an additional therapeutic option for patients with various neoplastic diseases and autoimmune conditions. The newly approved product includes both 50 mg/2 mL (25 mg/mL) multi-dose vials and 1g/40 mL (25 mg/mL) single-dose vials, offering a folate analog metabolic inhibitor that is therapeutically equivalent to the reference listed drug (RLD) produced by Hospira, Inc.
Main data supporting the findings
The FDA’s final approval of this ANDA signifies that Alembic Pharmaceuticals’ Methotrexate Injection meets the rigorous bioequivalence and manufacturing standards required to be classified as therapeutically equivalent to the reference listed drug, Methotrexate Injection USP, 50 mg/2 mL (25 mg/mL) and 1g/40 mL (25 mg/mL). As a folate analog metabolic inhibitor, the medication is indicated for a broad spectrum of neoplastic diseases. These include acute lymphoblastic leukemia, the prophylaxis and treatment of meningeal leukemia, and non-Hodgkin lymphoma. Furthermore, the drug is indicated for patients with osteosarcoma, breast cancer, squamous cell carcinoma of the head and neck, and gestational trophoblastic neoplasia.
Beyond its applications in oncology, the approval covers indications for several chronic inflammatory and autoimmune conditions. Patients with rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and severe psoriasis may also be treated with this formulation. This approval adds to Alembic Pharmaceuticals’ significant presence in the United States market, bringing their cumulative total to 236 ANDA approvals, which consists of 218 final approvals and 18 tentative approvals from the FDA.
Trial details
The approval of this ANDA is based on the determination that the product is the therapeutic equivalent of the RLD, Methotrexate Injection USP, manufactured by Hospira, Inc. This equivalence ensures that the 50 mg/2 mL (25 mg/mL) multi-dose vials and the 1g/40 mL (25 mg/mL) single-dose vials provide the same clinical effect and safety profile as the brand-name counterpart when administered to patients under the conditions specified in the labeling.
Alembic Pharmaceuticals, a vertically integrated research and development company headquartered in India, utilized its state-of-the-art manufacturing and research facilities to develop the application. These facilities are approved by various global regulatory authorities, including the USFDA. The company has been active in the healthcare sector since 1907 and operates as a publicly listed entity that markets generic pharmaceutical products globally. The development of this methotrexate formulation follows the company’s strategy of expanding its portfolio of branded generics, which are supported by a field force of over 5,500 professionals.
Safety
Methotrexate Injection is classified as a folate analog metabolic inhibitor, and its administration must be aligned with the detailed indications and dosing schedules found in the product label. While the press release confirms therapeutic equivalence to the RLD, healthcare providers, including oncology nurses, should refer to the full prescribing information for detailed safety protocols and a comprehensive list of indications.
The product is indicated for serious conditions ranging from acute lymphoblastic leukemia to severe psoriasis, and appropriate clinical monitoring is required to manage its role as a metabolic inhibitor. The availability of both single-dose and multi-dose vials provides flexibility in clinical settings, though practitioners must adhere to standard safety guidelines regarding the use of multi-dose vials to prevent contamination and ensure patient safety.